biostudies-literatureJiang CShanghai Pudong Scientific and Technological development ProjectsNational Natural Science Foundation of ChinaNational Key Research and Development Program of China275-286https://www.ebi.ac.uk/biostudies/studies/S-EPMC9816240biostudies-literatureUnknown50(2)Radionuclides theranostic are ideal "partners" for bispecific antibodies to explore the immune response of patients and synergistic treatment. A bispecific single-domain antibody-Fc fusion protein, KN046, exhibits a good treatment effect by binding to programmed cell death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). An ionizing-radiation stimulus mediated by a low-dose of [¹³¹I] may be used for immunopotentiation. In this study, we established [¹³¹I]-labeled KN046 as a novel radioimmunotherapy agent to treat malignant melanoma and explored the mechanism.<h4>Methods</h4>After intravenous injection of [¹³¹I]-KN046, SPECT/CT imaging was applied to identify candidate targets for KN046 immunotherapy. [¹⁸F]-FDG and [<sup>European journal of nuclear medicine and molecular imagingEnhanced antitumor immune responses via a new agent [¹³¹I]-labeled dual-target immunosuppressant.PMC9816240PKJ2020-Y55819716482020YFA0909000He SYang ZChen JZhang JLi PSong SJiang CYao BXu XTian QfalseEnhanced antitumor immune responses via a new agent [¹³¹I]-labeled dual-target immunosuppressant.Radionuclides theranostic are ideal "partners" for bispecific antibodies to explore the immune response of patients and synergistic treatment. A bispecific single-domain antibody-Fc fusion protein, KN046, exhibits a good treatment effect by binding to programmed cell death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). An ionizing-radiation stimulus mediated by a low-dose of [¹³¹I] may be used for immunopotentiation. In this study, we established [¹³¹I]-labeled KN046 as a novel radioimmunotherapy agent to treat malignant melanoma and explored the mechanism.<h4>Methods</h4>After intravenous injection of [¹³¹I]-KN046, SPECT/CT imaging was applied to identify candidate targets for KN046 immunotherapy. [¹⁸F]-FDG and [<sup>2023-01-01T00:00:00Z2023 Jan2025-04-21T16:16:21.983Z2025-02-19T03:30:52.642ZS-EPMC98162403624261610.1007/s00259-022-05986-4